Evaluation of the prophylactic effect of tranexamic acid in von willebrand disease and glanzman thrombasthenia

Not Applicable

• Conditions: Condition 1: Glanzmann thrombasthenia. Condition 2: Von Willebrand.; Qualitative platelet defects; Von Willebrand disease

• Registration Number: IRCT2015111525031N2
• Lead Sponsor: Vice Chancellor for research of Arak University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

All patients with a von Willebrand I, II, III and Glanzmann thrombasthenia which they records are included in Arak Amir-Kabir Hospital.;

Exclusion criteria:
(a)Patients who have a history of thrombosis;
(b)Patients who do not consent to the inclusion;
(c)Patients with hepatitis B or C;
(d)Patients with liver or renal dysfunction;
(e)Patients with local bleeding lesions such as hemangiomas or local wound;
(f)Younger than 2 years;
(g)Patients who can not tolerate the gastrointestinal drug;

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The number of bleeding attacks. Timepoint: before and six months after intervention. Method of measurement: counting frequency.;The severity of bleeding. Timepoint: before and six months after intervention. Method of measurement: visual scale and assigned a grade from one to four.;The number of used concentrates. Timepoint: before and six months after intervention. Method of measurement: counting frequency.